Differences in mode of action of β-lactam antibiotics influence morphology, LPS release and in vivo antibiotic efficacy

Journal of Endotoxin Research

Volumn 3, Issue 3, 1996, Pages 201-218

  Jackson, Jesse J ^a   Kropp, Helmut ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BACTERIUM LIPOPOLYSACCHARIDE; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARRAGEENAN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CYTOKINE; DACTINOMYCIN; ENDOTOXIN; IMIPENEM; MEROPENEM; MONOBACTAM DERIVATIVE; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; BINDING AFFINITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; GRAM NEGATIVE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MORPHOLOGY; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA; BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0029781404     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199600300306     Document Type: Conference Paper

References (43)

1. Shenep J.L., Flynn P.M., Barrett F.F., Stidham G.L., Westenkirchner D.F. Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative bacterial sepsis. J Infect Dis 1988; 157: 565-568.
2. Anderson B.M., Solberg O. The endotoxin liberating effect of antibiotics on Meningococcus in vitro. Acta Path Microbiol Scand 1980; 88: 231-236.
3. Anderson B.M., Solberg O. Release of endotoxin from Neisseria meningitidis. A short survey with a preliminary report on virulence in mice. NIPH Ann 1980; 3: 49-55.
4. Russel R.B.B. Free endotoxin - a review. Microbios Lett 1976; 2: 125-135.
5. Dofferhoff A.S.M., Nijland J.H., de Vries-Hospers H.G., Mulder P.O.M., Weits J., Bom V.J.J. Effects of different types and combinations of antimicrobial agents on endotoxin release from Gram-negative bacteria: an in vitro and in vivo study. Scand J Infect Dis 1991; 23: 745-754.
6. Arditi M., Ables L., Yogev R. Cerebrospinal fluid endotoxin levels in children with H. influenza meningitis before and after administration of intravenous ceftriaxone. J Infect Dis 1989; 160: 1005-1011.
7. Brandtzaeg P., Kierulf P., Gaustad P. et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195-204.
8. Fry D.E., Pearlstein L., Fulton R.L., Polk H.C. Multiple system organ failure. The role of uncontrolled infection. Arch Surg 1980; 115: 136-140.
9. Simon D.M., Koenig G., Trenholme G.M. Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic killed Escherichia coli. J Infect Dis 1991; 164: 800-802.
10. CDC. Increase in national hospital discharge survey rates for septicemia. United States 1979-1987. MMWR 1987; 39: 31-34.
11. Arditi M., Rabat W., Vogev R. Antibiotic-induced bacterial killing stimulates tumor necrosis factor-alpha release in whole blood. J Infect Dis 1993; 167: 240-244.
12. Eng R.H., Smith S.M., Fan-Harvard P., Ogbara T. Effects of antibiotics on endotoxin release from Gram-negative bacteria. Diagn Microbiol Infect Dis 1993; 16: 185-189.
13. Bucklin S.E., Fujihara Y., Leeson M.C., Morrison D. Differential antibiotic induced release of endotoxin from Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1994; 13 (Suppl 1): S43-S51.
14. Bingen E., Goury V., Bennani H., Lambert-Zechovsky N., Aujard Y., Darbord J.C. Bactericidal activity of beta-lactam antibiotics and amikacin against Haemophihis influenza: effect on endotoxin release. J Antimicrob Chemother 1993; 30: 165-172.
15. Jackson J.J., Kropp H. Beta-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infecf Dis 1992; 165: 1033-1041.
16. Flynn P.M., Shenep J.L., Gigliotti F., Davis D.S., Hildner W.K. Immunolabeling of LPS liberated from antibiotic-treated Escherichia coli. Infect Immun 1988; 56: 2760-2762.
17. Shenep J.L., Barto R.P., Morgan K.A. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental Gram-negative bacterial sepsis. J Infect Dis 1985; 151: 1012-1018.
18. Walterspiel J.W., Kaplan S.L., Mason E.O. Protective effect of subinhibitory polymyxin B alone and in combination with ampicillin for overwhelming Haemophihis influenza type B infection in the infant rat: evidence for in vivo and in vitro release of free endotoxin after ampicillin treatment. Pediatr Res 1986; 20: 237-241.
19. Symonds W.T., Hyatt J.M., Gagliardi N., Holden P., Nix D.E. Comparative effects of L-627 (L), imipenem (I), and ceftazidime (C) on in vitro production and release of endotoxin. (Session 17, Abstract F27). In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL, USA). Washington, DC: American Society for Microbiology, 1994; 31.
20. Jackson J.J., Kropp H. Reply: beta-lactam antibiotic-induced release of lipopolysaccharide. J Infect Dis 1993; 167: 775-777.
21. Buijs J., Dofferhoff A.S.M. Antibiotic induced endotoxin release is type, dose and dosing schedule dependent (Session 75, Abstract A97). In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL, USA). Washington, DC: American Society for Microbiology, 1994; 147.
22. Dofferhoff A.S.M., Bom V.J.J., van Ingen J. et al. Patterns of cytokines, plasma endotoxin and acute phase proteins during the treatment of severe sepsis in humans. Prog Clin Biol Res 1991; 367: 43-54.
23. Dofferhoff A.S.M., Potthoff H., Bom V.J.J. et al. The release of endotoxin, TNF and IL-6 during the antibiotic treatment of experimental Gram-negative sepsis. J Endotoxin Res 1995; 2: 37-44.
24. Jackson J.J., Kropp H. Variations in β-lactam antibiotic-induced release of endotoxin: in vivo relevance. In: Morrison D.C., Ryan J.L. Eds. Novel Therapeutic Strategies in the Treatment of Sepsis. New York: Marcel Dekker, 1995; 325-346.
25. Neu H.C. Carbapenems: special properties contributing to their activity. Am J Med 1985; 78: 33-40.
26. Toumanen E., Tomasz A. Induction of autolysis in non-growing Escherichia coli. J Bacteriol 1986; 167: 1077-1080.
27. Wientjes F.B., Nanninga N. On the role of high molecular weight penicillin-binding proteins in the cell cycle of Escherichia coli. Res Microbiol 1991; 142: 333-344.
28. Sumita Y., Fukasawa M., Okuda T. Comparison of two carbapenems, SM-7338 and imipenem; affinities for penicillin-binding proteins and morphological changes. J Antibiot 1990; 43: 314-320.
29. Drusano G.L., Standiford H.C., Bustamante C. et al. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother 1984; 26: 715-721.
30. Bax R.P., Bastain W., Featherstone A., Wilkinson D.M., Hutchinson M., Haworth S.J. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24 (Suppl A): 311-320.
31. Harding S.M., Monro A.J., Thornton J.E., Ayrton J., Hogg M.I.J. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother 1991; 8 (Suppl B): 263-272.
32. Van den Berg C., De Neeling W.N.M., Schot C.S., Hustinx W.N.M., Wemer J., De Wildt D.J. Delayed antibiotic-induced lysis of E. coli in vitro is correlated with enhancement of LPS release. Scand J Infect Dis 1992; 24: 619-627.
33. Bucklin S.E., Morrison D.C. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of Gram-negative sepsis. J Infect Dis 1995; 172: 1519-1527.
34. Whelan A.C. E. coli damaged by antibiotics. ASM News 1993; 59: 225.
35. Foca A., Matera G., Iannello D., Berlinghieri M.C., Liberto M.C. Aminoglycosides modify the in vitro metachromatic reaction and murine generalized Shwartzman phenomenon induced by Salmonella minnesota R595 lipopolysaccharide. Antimicrob Agents Chemother 1991; 35: 2161-2164.
36. Luo G., Niesel D.W., Shaban R.A., Grimm E.A., Wimpel G.R. Tumor necrosis factor alpha binding to bacteria: evidence for high-affinity receptors and alterations of bacterial virulence properties. Infect Immun 1993; 61: 830-835.
37. Koch T., Dunker H.P., Axt R., Schiefer H.G., van Ackern K., Neuhof H. Alterations of bacterial clearance induced by endotoxin and tumor necrosis factor. Infect Immun 1993; 61: 3143-3148.
38. Haranaka K., Satomi N., Sakurai A. Differences in tumor necrosis factor productive ability among rodents. Br J Cancer 1984; 50: 471-478.
39. Matsuura M., Galanos C. Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection with Salmonella typhimurium. Infect Immun 1990; 58: 935-937.
40. Rowe P.S.N., Meadow P.M. Structure of the core oligosaccharide from the LPS of P. aeruginosa PAC 1R and its defective mutants. Eur J Biochem 1983; 132: 329-337.
41. Thompson A.W., Fowler E.F. Carrageenan: a review of its effects on the immune system. Agents Actions 1981; 11: 265-273.
42. Tatsukawa K., Mitsuyama M., Takeya K., Nomoto K. Differing contributions of PMN cells and macrophages to protection of mice against Listeria monocytogenes and Pseudomonas aeruginosa. J Gen Microbiol 1979; 115: 161-166.
43. Sasaki K., Obana Y., Otsuki M., Kesado T., Nishino T. In vitro and in vivo antibacterial activity of L-627 with high stability of dehydropeptidase-1. (Abstract 818) In: Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Houston, TX), Washington, DC: American Society for Microbiology, 1991; 235.